

ASX Release 12 August 2024

ASX code: PIQ

### **Resignation of Director**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises Dr Robyn Elliott has resigned as a non-executive director of the Company, effective today due to personal commitments and following her retirement from CSL.

Proteomics International Laboratories Ltd Non-Executive Chairman Neville Gardiner said, "On behalf of the Board members I would like to express our gratitude to Dr Elliott for her valued contribution to the Company since November 2021 and wish her the very best in her future endeavours."

As previously announced the Company is in the process of recruiting the additional Board and management skills and experience necessary to support its commercialisation initiatives (ASX: 17 April 2024, 30 July 2024) and expects to provide further updates to the market during the next 3 months.

Following is Dr Elliott's Appendix 3Z – Final Director's Interest Notice.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

### About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

### For further information please contact:

Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com

Dirk van Dissel Investor Relations Candour Advisory T: +61 408 326 367 E: dirk@candouradvisory.com.au Lisa Barnes Public Relations Profile Media T: +61 416 583 672 E: lisab@profilemedia.com.au

Rule 3.19A.3

# Appendix 3Z

## **Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Robyn Elliott
Date of last notice	24 November 2022
Date that director ceased to be director	12 August 2024

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

### Number & class of securities

125,000 unquoted options exercisable at \$1.32 per option on or before 24 November 2025 (Director C Options).

125,000 unquoted options exercisable at \$1.76 per option on or before 24 November 2026 (Director D Options)

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Not applicable	Nil

### Part 3 – Director's interests in contracts

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

<sup>+</sup> See chapter 19 for defined terms.